NOTV:NASDAQInotiv, Inc. Analysis
Data as of 2026-05-19 - not real-time
$0.26
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Inotiv, Inc. (NOTV) is trading at $0.259, which sits well below its 20‑day SMA ($0.295) and 50‑day SMA ($0.304) and dramatically under the 200‑day SMA ($0.856), signaling a strong bearish price trend. The MACD line remains under its signal line, the RSI hovers at 44 (neutral‑to‑bearish), and the stock is testing a support level near $0.24 with resistance around $0.34. Volume is rising, yet the 30‑day volatility is extreme at 186% and beta exceeds 3, indicating the share price is highly sensitive to market swings.
Fundamentally, the company is in distress: revenue is $507 M but shrinking (-5.4% YoY), margins are deeply negative (operating –16%, profit –17%), and the balance sheet is overloaded with $483 M of debt versus just $15 M of cash (debt‑to‑equity 627). The price‑to‑book ratio of 0.12 suggests the market is pricing the equity far below its book value, but the negative ROE (‑74%) and lack of dividend underscore the financial fragility.
Fundamentally, the company is in distress: revenue is $507 M but shrinking (-5.4% YoY), margins are deeply negative (operating –16%, profit –17%), and the balance sheet is overloaded with $483 M of debt versus just $15 M of cash (debt‑to‑equity 627). The price‑to‑book ratio of 0.12 suggests the market is pricing the equity far below its book value, but the negative ROE (‑74%) and lack of dividend underscore the financial fragility.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 9/10
Key Factors
- Bearish technicals (price below 20‑day SMA and MACD histogram negative)
- Extreme short‑term volatility (186% 30‑day) and high beta (3.27)
- Severe financial distress (debt‑to‑equity 627, negative earnings)
Medium Term
1–3 yearsCautious
Model confidence: 8/10
Key Factors
- Continued negative margins and earnings outlook
- Insufficient cash flow to service massive debt load
- Market cap of only $9 M makes the stock vulnerable to price shocks
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Very low price‑to‑book ratio (0.12) could provide upside if restructuring occurs
- Potential strategic acquisition or asset sale in the contract research space
- Long‑run demand for non‑clinical drug discovery services may stabilize earnings
Key Metrics & Analysis
Financial Health
Revenue Growth-5.40%
Profit Margin-17.14%
P/E Ratio-5.2
ROE-74.09%
ROA-4.61%
Debt/Equity627.14
P/B Ratio0.1
Op. Cash Flow$354.0K
Free Cash Flow$20.6M
Industry P/E26.9
Technical Analysis
TrendBearish
RSI43.7
Support$0.24
Resistance$0.34
MA 20$0.30
MA 50$0.30
MA 200$0.86
MACDBearish
VolumeIncreasing
Fear & Greed Index89.39
Valuation
Target Price$3.25
Upside/Downside1154.83%
GradeUndervalued
TypeValue
Risk Assessment
Beta3.27
Volatility186.71%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.